Lila Levinson, PhD,  Science Writer—

The first participant has been dosed in a Phase 2b clinical trial testing BiomX’s experimental inhaled therapy BX004 in adults with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa lung infection. “This first patient dosing marks a significant milestone for our BX004 program and for CF patients with chronic P.

Alyftrek has been approved by the European Commission to treat cystic fibrosis (CF) patients 6 years and older who have at least one non-class 1 mutation in the CFTR gene. This indication in the European Union (EU) represents the broadest label for Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) in the world, according to the…

Although infants with cystic fibrosis (CF) may have lung function abnormalities between the ages of 3 months and 2 years, these are predominantly mild and temporary, a real-world study reports. Tests that indicate abnormal lung function may influence decisions about clinical management of CF. Clinical findings, however, including evidence…

SION-719 and SION-451, two NBD1 stabilizers Sionna Therapeutics is developing to restore CFTR protein function in cystic fibrosis (CF), will advance to the next stages of clinical development after positive safety results in Phase 1 clinical trials. Sionna tested both compounds in healthy volunteers to assess safety and…